COMMUNIQUÉS West-GlobeNewswire

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
02/01/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN [...]
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
02/01/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the [...]
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
01/01/2025
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s [...]
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
31/12/2024
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term cash needs SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq [...]
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
31/12/2024
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar Reduction CHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health Plus , a leader in regenerative medicine, is introducing [...]
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
31/12/2024
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Firefly Neuroscience Closes on Financing of up to $12.4 Million
31/12/2024
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31/12/2024
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA [...]
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
31/12/2024
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Vireo Growth Inc. Announces Closing of Oversubscribed US$81 Million Equity Securities Offering
31/12/2024
– Oversubscribed equity raise at US$0.625 per share capitalizes Company with a strong balance sheet– – Financing enables Vireo to fund investments in additional organic and acquisitive growth opportunities – MINNEAPOLIS [...]
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
31/12/2024
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations Enrollment to be extended due to low influenza infection among challenged participants [...]
Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants
31/12/2024
DALLAS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in [...]
Making Cancer Drugs Safer: CellMosaic CEO to Host Live Investment Webinar
31/12/2024
DoD-recognized biotech company opens investment round as its cancer treatment technology gains traction with 159+ global organizations. Woburn, MA, Dec. 31, 2024 (GLOBE NEWSWIRE) -- CellMosaic CEO Dr. Yumei Huang will [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/12/2024
CLEVELAND, , Dec. 31, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Oncotelic Therapeutics Implements PDAOAI Platform
31/12/2024
AGOURA HILLS, Calif., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), today announced the implementation of its artificial intelligence (AI) [...]
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
31/12/2024
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova [...]
Burning Rock Announces Results of 2024 Annual General Meeting
31/12/2024
GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ Company ” or “ Burning Rock ”), a company focusing on the application of next generation sequencing (NGS) technology [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
31/12/2024
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 30 décembre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
31/12/2024
Déclaration de transactions sur actions propres Paris, France (31 décembre 2024, 8h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que du 24 décembre 2024 [...]

Pages